OmniAb, Inc.

OmniAb, Inc. licenses advanced discovery research technology to pharmaceutical and biotech companies and academic institutions to facilitate the discovery of next-generation therapeutics. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for drug development. The core of the OmniAb platform, termed Biological Intelligence™, utilizes the immune systems of proprietary, engineered transgenic animals to generate optimized antibody candidates for human therapeutics. OmniAb's animals include OmniRat®, OmniChicken®, and OmniMouse®, which are genetically modified to produce antibodies with human sequences. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed for bispecific antibody discovery. OmniTaur™ provides cow-inspired antibodies for challenging targets, and Omni dAb™ is an in vivo platform for single-domain antibody discovery using a human VH scaffold that matures in a chicken host. The company's technologies include computational antigen design, immunization methods, high-throughput single B cell phenotypic screening, and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies. OmniAb offers both integrated end-to-end capabilities and customizable solutions. Its business model involves structured platform license agreements that typically include upfront or annual access fees, service revenue, milestones, and royalties on commercial sales. As of December 31, 2025, OmniAb had 107 active partners with 407 active programs using its technology platform. This includes 27 OmniAb-derived antibodies in clinical development by partners, two under regulatory review, and three approved products developed and commercialized by partners.